Biotechnology Companies' Quarterly Results - Research Report on Geron, Santarus, Merrimack, Clovis, and Arena

    Biotechnology Companies' Quarterly Results - Research Report on Geron,
                    Santarus, Merrimack, Clovis, and Arena

PR Newswire

NEW YORK, November 12, 2013

NEW YORK, November 12, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Geron
Corporation (NASDAQ: GERN), Santarus, Inc. (NASDAQ: SNTS), Merrimack
Pharmaceuticals, Inc. (NASDAQ: MACK), Clovis Oncology, Inc. (NASDAQ: CLVS),
and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Geron Corporation Research Report

On November 7, 2013, Geron Corporation (Geron) released its Q3 2013 results.
Geron registered revenues of c.$0.2 million in Q3 2013, compared to revenues
of c.$0.6 million in Q3 2012. The Company posted net loss of $8.3 million in
Q3 2013, compared to net loss of $16.0 million in Q3 2012. Geron reported
diluted loss per share of $0.06 in Q3 2013, compared to diluted loss per share
of $0.13 in Q3 2012. The Full Research Report on Geron Corporation - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/1ca9_GERN]

Santarus, Inc. Research Report

On November 7, 2013, Santarus, Inc. (Santarus) released its Q3 2013 results.
Santarus registered total revenues of $98.8 million in Q3 2013, up 80.7% YoY.
The Company posted net income of $30.3 million in Q3 2013, up 237.5% YoY.
Santarus reported diluted EPS of $0.38 in Q3 2013, up 192.3% YoY. The Full
Research Report on Santarus, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/22f8_SNTS]

Merrimack Pharmaceuticals, Inc. Research Report

On November 7, 2013, Merrimack Pharmaceuticals, Inc. (Merrimack) released its
Q3 2013 results. Merrimack registered collaboration revenues of $11.3 million
in Q3 2013, up 65.2% YoY. The Company posted net loss attributable to
Merrimack of $23.2 million in Q3 2013, compared to net loss attributable to
Merrimack of $39.6 million in Q3 2012. Merrimack reported diluted loss per
share of $0.25 in Q3 2013, compared to diluted loss per share of $0.39 in Q3
2012. The Company expects its existing unrestricted cash and cash equivalents
and available-for-sale securities as of September 30, 2013 of $182.5 million,
anticipated interest income and funding under its license and collaboration
agreement with Sanofi related to MM-121 to be sufficient to fund operations
into 2015. Merrimack informed that if it achieves favorable results from the
MM-398 NAPOLI-1 trial, the Company expects anticipated additional expenses in
2014 related to the commercialization of MM-398 to be offset by cash received
from potential collaboration opportunities. The Full Research Report on
Merrimack Pharmaceuticals, Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/8bb0_MACK]

Clovis Oncology, Inc. Research Report

On October 31, 2013, Clovis Oncology, Inc. (Clovis) released its Q3 2013
results. Clovis registered net loss of $20.3 million in Q3 2013, compared to
net loss of $18.3 million in Q3 2012. The Company posted diluted net loss per
common share of $0.68 in Q3 2013, compared to diluted net loss per common
share of $0.71 in Q3 2012. Commenting on the Company's clinical development
programs, Patrick J. Mahaffy, President and CEO of Clovis, said, "We are very
pleased by the data recently presented for both CO-1686 and rucaparib and the
progress being made on both programs." Mahaffy continued, "Given the
encouraging results we've seen for CO-1686 to date, we look forward to
identifying the Phase 2 dose with our improved HBr formulation by the end of
2013, and then commencing our initial registration study in the first half of
2014. This will be our first pivotal trial of a broad and global clinical
development plan for CO-1686." The Full Research Report on Clovis Oncology,
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/6a2a_CLVS]

Arena Pharmaceuticals, Inc. Research Report

On November 7, 2013, Arena Pharmaceuticals, Inc. (Arena) released its Q3 2013
results. Arena registered total revenues of $3.6 million in Q3 2013, up 140.9%
YoY. The Company posted net loss allocable to common shareholders of $17.2
million in Q3 2013, compared to net loss allocable to common shareholders of
$15.5 million in Q3 2012. Arena reported diluted loss per share of $0.08 in Q3
2013, compared to diluted loss per share of $0.07 in Q3 2012. Jack Lief,
Arena's President and CEO, stated, "We are excited by our expanded agreement
with Eisai and look forward to collaborating as we focus on the global
registration and commercialization of BELVIQ for weight management and the
development of potential new indications." Lief continued, "Our third quarter
results reflect the first full quarter since BELVIQ became available in US
pharmacies. Additional work is needed to continue building the weight
management market, and we are pleased with Eisai's commitment to realizing the
medical and commercial potential of BELVIQ. We look forward to the market
growth of this important treatment option as we move into 2014." The Full
Research Report on Arena Pharmaceuticals, Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

[http://www.AnalystsCorner.com/r/full_research_report/6a95_ARNA]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to making mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.AnalystsCorner.com/

SOURCE Analysts' Corner

Contact: CONTACT PERSON: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North
America)
 
Press spacebar to pause and continue. Press esc to stop.